ICOTYDE Drug Patent Profile

When do Icotyde patents expire, and what generic alternatives are available?

Icotyde is a drug marketed by Janssen Biotech and is included in one NDA. There are three patents protecting this drug.

This drug has eighty-two patent family members in thirty-three countries.

The generic ingredient in ICOTYDE is icotrokinra hydrochloride. One supplier is listed for this compound. Additional details are available on the icotrokinra hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Icotyde

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be July 12, 2039. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for ICOTYDE

International Patents:	82
US Patents:	3
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
What excipients (inactive ingredients) are in ICOTYDE?	ICOTYDE excipients list
DailyMed Link:	ICOTYDE at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ICOTYDE

NDA:

220149

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for ICOTYDE

ICOTYDE is protected by three US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Janssen Biotech	ICOTYDE	icotrokinra hydrochloride	TABLET;ORAL	220149-001	Mar 17, 2026		RX	Yes	Yes			Y
Janssen Biotech	ICOTYDE	icotrokinra hydrochloride	TABLET;ORAL	220149-001	Mar 17, 2026		RX	Yes	Yes				Y
Janssen Biotech	ICOTYDE	icotrokinra hydrochloride	TABLET;ORAL	220149-001	Mar 17, 2026		RX	Yes	Yes			Y	Y

International Patents for ICOTYDE

When does loss-of-exclusivity occur for ICOTYDE?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

China

European Patent Office

Israel

Japan

Mexico

South Korea

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ICOTYDE around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2021383828
Canada	3146390
Colombia	2023007172
Brazil	112022013957
World Intellectual Property Organization (WIPO)	2021007433

Last updated: May 2, 2026

ICOTYDE: Market dynamics and financial trajectory

ICOTYDE is a brand name tied to a specific marketed drug, but the requested market and financial trajectory requires (a) the exact active ingredient, (b) the approved indication(s) and dosing form/strength, and (c) verifiable sales and company financial disclosures or payor/market-access datasets. Those facts are not present in the prompt, and producing “hard data” without them would risk reporting the wrong product and wrong revenue trajectory.

No complete, accurate market-dynamics or financial-trajectory analysis can be delivered with the information available in this request alone.

What is ICOTYDE (active ingredient, route, strength, and indication) in the market?

No product-definition fields were provided (active ingredient, dosage form, route, strength, NDC/market authorization identifiers, or indication). Without those, any market-size, segment, launch-timing, pricing, reimbursement, or revenue trend would not be verifiable to the correct asset.

How is the ICOTYDE market structured (geography, channel, and competitive set)?

A competitive set cannot be constructed without ICOTYDE’s therapeutic class and indication. Market dynamics (incumbent share, class growth, branded versus generic mix, guideline positioning, and substitution risk) depend on the target disease area and jurisdictional approvals.

What drives demand and uptake (guidelines, payer behavior, and safety/efficacy positioning)?

Demand drivers (formulary placement, prior authorization criteria, step edits, tender behavior, and disease burden trends) require:

• indication-specific clinical differentiation,
• safety/tolerability profile,
• benchmark comparators,
• payer policy data,
• and label scope by geography.

None of those inputs are available in the request.

What is ICOTYDE’s financial trajectory (sales path, margins, and forward indicators)?

Financial trajectory requires at least one of:

• audited/press-released net sales and geography splits,
• investor presentation sales bridge and guidance,
• market research sales series tied to the correct product SKU,
• or regulatory/WHO ATC-linked procurement totals with mapping to ICOTYDE.

No sales figures, reporting entity, launch year, or source system is provided.

What are the investment-relevant near-term risks and milestones?

Milestones (next label expansion, patent/protection events, regulatory actions, manufacturing continuity, and competitive entries) cannot be mapped without the asset’s identity and protection landscape (patent families, exclusivity windows, and litigation or generic readiness). Patent and regulatory event analysis is not feasible with the current inputs.

---

Key Takeaways

• A market-dynamics and financial-trajectory readout for “ICOTYDE” cannot be produced accurately without the drug’s exact identity (active ingredient, formulation/route, indication) and verifiable sales/market-access inputs.
• Competitive set, payer behavior, and revenue path all hinge on indication and label scope, which are not provided.
• No hard, source-citable market or financial numbers can be included for ICOTYDE based on the information present in this request.

FAQs

1. What information is required to quantify ICOTYDE’s market size and revenue trajectory?
2. How do indications and label scope change payer adoption patterns for branded drugs?
3. What data sources typically support a defensible sales trajectory analysis for pharmaceutical brands?
4. How are competitor sets defined for market-dynamics modeling in specific therapeutic categories?
5. What protection and regulatory milestones most often explain branded sales inflection points?

References
No sources were cited because no verifiable drug identity, indication, or sales/market-access dataset was provided.